These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1811387)

  • 21. [Cell-free Pseudomonas vaccine. II. Isolation and immunological properties of protective antigens of Pseudomonas aeruginosa].
    Stanislavskiĭ ES; Palkina NA; Bulk VF; Zhvanetskaia MI; Chekan LV
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):37-40. PubMed ID: 6797158
    [No Abstract]   [Full Text] [Related]  

  • 22. Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers.
    Martindale JJ; Ganzinger U; Steinmüller W; Millendorfer A; Ambrosch F; Kollaritsch H; Wiedermann G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 May; 268(3):376-85. PubMed ID: 3136608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
    Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
    Larbig M; Mansouri E; Freihorst J; Tümmler B; Köhler G; Domdey H; Knapp B; Hungerer KD; Hundt E; Gabelsberger J; von Specht BU
    Vaccine; 2001 Mar; 19(17-19):2291-7. PubMed ID: 11257350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity evaluating of the SLNs-alginate conjugate against Pseudomonas aeruginosa.
    Afshari H; Maleki M; Hakimian M; Tanha RA; Salouti M
    J Immunol Methods; 2021 Jan; 488():112938. PubMed ID: 33259781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 30. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.
    Price BM; Barten Legutki J; Galloway DR; von Specht BU; Gilleland LB; Gilleland HE; Staczek J
    FEMS Immunol Med Microbiol; 2002 Jun; 33(2):89-99. PubMed ID: 12052563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The reactogenicity and antigenic activity of a meningococcal group B vaccine made from a natural complex of the specific polysaccharide and outer membrane proteins].
    Basnak'ian IA; Alliluev AP; Kuvakina VI; Levina LA; Krasnoproshina LI; Kotel'nikova OV; Karabak VI; Mordvitskiĭ AM; Borovkova VM; Aleksakhina NN
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Dec; (12):50-5. PubMed ID: 2129147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
    Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [An antigenic analysis and the protective properties of the R-form lipopolysaccharides of gram-negative bacteria].
    Stanislavskiĭ ES; Makarenko TA; Kholodkova EV; Lugowski C
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):52-6. PubMed ID: 9783402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunoenzyme analysis method for detecting anti-Pseudomonas aeruginosa antibodies in persons inoculated with pyoimmunogen].
    Severtsova MK; Vaĭda MB; Varró R
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jan; (1):55-9. PubMed ID: 3920846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antigenic complexes of Pseudomonas aeruginosa slime: their isolation and biological properties].
    Aleksandrov AD; Antsiferova NG; Zhmyrina TI; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):14-9. PubMed ID: 6422680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preventive properties of the blood sera from persons vaccinated with a Proteus vaccine made from soluble antigen complexes].
    Levina LA; Kreĭnin LS; Kaverina KG; Zdanovskaia LK; Iurova VA
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):84-8. PubMed ID: 3087123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.
    Elhosary MA; Bahey-El-Din M; AbdelBary A; El Guink N; Aboushleib HM
    Microb Pathog; 2019 Jun; 131():181-185. PubMed ID: 30978430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of a polyvalent erythrocyte diagnostic agent for determining antibodies to Pseudomonas aeruginosa in clinical practice].
    Aleksandrova IA; Titova TI; Aleksandrov AD; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Jan; (1):46-50. PubMed ID: 2496541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective mechanisms of experimental vaccine-induced immunity to Pseudomonas aeruginosa.
    Lieberman MM
    Surv Synth Pathol Res; 1985; 4(4):312-22. PubMed ID: 3939159
    [No Abstract]   [Full Text] [Related]  

  • 40. [Dynamic anti-Proteus immunity in plasma donors during plasmapheresis].
    Nazarchuk LV; Fedorovskaia EA
    Vrach Delo; 1991 May; (5):35-8. PubMed ID: 1866911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.